IL236651B - Antibodies against the dr5 family, bispecific or multivalent antibodies against the dr5 family and methods of using them - Google Patents

Antibodies against the dr5 family, bispecific or multivalent antibodies against the dr5 family and methods of using them

Info

Publication number
IL236651B
IL236651B IL23665115A IL23665115A IL236651B IL 236651 B IL236651 B IL 236651B IL 23665115 A IL23665115 A IL 23665115A IL 23665115 A IL23665115 A IL 23665115A IL 236651 B IL236651 B IL 236651B
Authority
IL
Israel
Prior art keywords
family antibodies
bispecific
methods
multivalent
antibodies
Prior art date
Application number
IL23665115A
Other languages
English (en)
Hebrew (he)
Other versions
IL236651A0 (en
Inventor
Brigitte Fernande Vermot-Desroches Claudine
Frederic Subiger Olivier
Francoise Jeanne-Marie Bourdin Laurence
Original Assignee
Claudine Brigitte Fernande Vermot Desroches
Frederic Subiger Olivier
Laurence Francoise Jeanne Marie Bourdin
Genmab Bv
Int Drug Development Biotech
Genmab Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claudine Brigitte Fernande Vermot Desroches, Frederic Subiger Olivier, Laurence Francoise Jeanne Marie Bourdin, Genmab Bv, Int Drug Development Biotech, Genmab Holding B V filed Critical Claudine Brigitte Fernande Vermot Desroches
Publication of IL236651A0 publication Critical patent/IL236651A0/en
Publication of IL236651B publication Critical patent/IL236651B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL23665115A 2012-07-09 2015-01-11 Antibodies against the dr5 family, bispecific or multivalent antibodies against the dr5 family and methods of using them IL236651B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305821.6A EP2684896A1 (en) 2012-07-09 2012-07-09 Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
US201261669866P 2012-07-10 2012-07-10
PCT/EP2013/064466 WO2014009358A1 (en) 2012-07-09 2013-07-09 Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
IL236651A0 IL236651A0 (en) 2015-02-26
IL236651B true IL236651B (en) 2019-10-31

Family

ID=46514282

Family Applications (2)

Application Number Title Priority Date Filing Date
IL23665115A IL236651B (en) 2012-07-09 2015-01-11 Antibodies against the dr5 family, bispecific or multivalent antibodies against the dr5 family and methods of using them
IL269527A IL269527B (en) 2012-07-09 2019-09-22 Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL269527A IL269527B (en) 2012-07-09 2019-09-22 Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof

Country Status (15)

Country Link
US (4) US9611327B2 (enExample)
EP (3) EP2684896A1 (enExample)
JP (1) JP6457386B2 (enExample)
CN (1) CN104619725B (enExample)
BR (1) BR112015000449B1 (enExample)
CA (1) CA2878790C (enExample)
DK (1) DK2877491T3 (enExample)
ES (1) ES2727486T3 (enExample)
IL (2) IL236651B (enExample)
IN (1) IN2015DN00143A (enExample)
PL (1) PL2877491T3 (enExample)
PT (1) PT2877491T (enExample)
SG (2) SG11201500177PA (enExample)
SI (1) SI2877491T1 (enExample)
WO (1) WO2014009358A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3247728T (pt) 2015-01-20 2020-07-16 Igm Biosciences Inc Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas
EP3048116A1 (en) * 2015-01-23 2016-07-27 International-Drug-Development-Biotech Anti-dr5 antibodies with enhanced apoptosis potency
CN107250161A (zh) * 2015-01-26 2017-10-13 宏观基因有限公司 包含dr5‑结合结构域的多价分子
EP3112381A1 (en) * 2015-07-01 2017-01-04 FONDAZIONE IRCCS Istituto Nazionale dei Tumori Bispecific antibodies for use in cancer immunotherapy
JP6807606B2 (ja) 2015-07-16 2021-01-06 インヒブルクス インコーポレイテッド 多価及び多重特異性ｄｒ５結合融合タンパク質
MX2018006333A (es) 2015-12-01 2018-08-01 Genmab Bv Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos.
CN106397594B (zh) * 2016-10-25 2019-06-04 中国药科大学 一种全人源的抗人死亡受体5的激动剂单链抗体及应用
EP3535291A1 (en) 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
BR112019015900A2 (pt) 2017-02-10 2020-04-07 Genmab B.V. polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição
KR101926834B1 (ko) * 2017-03-21 2018-12-07 동아에스티 주식회사 항-dr5 항체 및 그의 용도
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
US12649798B2 (en) 2018-01-24 2026-06-09 Genmab B.V. Polypeptide variants and uses thereof
EP3759229A4 (en) * 2018-02-26 2021-12-29 IGM Biosciences Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
US12247075B2 (en) * 2018-12-26 2025-03-11 Imcheck Therapeutics Sas BTN3A binding proteins and uses thereof
US20220315661A1 (en) 2019-05-09 2022-10-06 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
JP7880817B2 (ja) 2019-11-06 2026-06-26 ジェンマブ ビー．ブイ． 抗体変種の組み合わせおよびその使用
US20230293680A1 (en) 2020-07-23 2023-09-21 Genmab B.V. A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
JP2025510548A (ja) * 2022-03-02 2025-04-15 ウォルデン バイオサイエンシズ，インコーポレイティド 新規の可溶性ウロキナーゼ型プラスミノーゲン活性化因子受容体（ｓｕＰＡＲ）結合性分子及びその使用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
CA2318029C (en) * 1998-01-15 2009-05-19 Genentech, Inc. Apo-2 ligand
EP1049787B1 (en) 1998-01-23 2004-11-24 Vlaams Interuniversitair Instituut voor Biotechnologie Multipurpose antibody derivatives
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
ATE330972T1 (de) 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
US6444640B1 (en) 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
GB0020442D0 (en) 2000-08-18 2000-10-04 Nokia Networks Oy Data transmission protocol
US20020155109A1 (en) 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
MXPA03010747A (es) 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
JP4509570B2 (ja) 2001-07-03 2010-07-21 ジェネンテック， インコーポレイテッド ヒトｄｒ４抗体及びその使用法
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
WO2006093794A1 (en) 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
JP2009529331A (ja) 2006-03-10 2009-08-20 マクロジェニクス，インコーポレーテッド 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法
KR100847010B1 (ko) * 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
WO2009002947A2 (en) 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування

Also Published As

Publication number Publication date
CA2878790C (en) 2023-09-26
IL269527B (en) 2021-12-01
DK2877491T3 (da) 2019-06-03
US20200332016A1 (en) 2020-10-22
BR112015000449A2 (enExample) 2017-08-15
PL2877491T3 (pl) 2020-01-31
EP2877491A1 (en) 2015-06-03
SG10201700148UA (en) 2017-02-27
US9611327B2 (en) 2017-04-04
BR112015000449B1 (pt) 2022-12-20
ES2727486T3 (es) 2019-10-16
EP3575323B1 (en) 2024-09-11
PT2877491T (pt) 2019-06-07
IL236651A0 (en) 2015-02-26
US20240141057A1 (en) 2024-05-02
SI2877491T1 (sl) 2019-08-30
IN2015DN00143A (enExample) 2015-06-12
WO2014009358A1 (en) 2014-01-16
CN104619725A (zh) 2015-05-13
EP2684896A1 (en) 2014-01-15
HK1211044A1 (en) 2016-05-13
CN104619725B (zh) 2019-04-23
JP6457386B2 (ja) 2019-01-23
US10647774B2 (en) 2020-05-12
CA2878790A1 (en) 2014-01-16
US20170260281A1 (en) 2017-09-14
JP2015527992A (ja) 2015-09-24
SG11201500177PA (en) 2015-03-30
EP3575323A1 (en) 2019-12-04
US20150139997A1 (en) 2015-05-21
EP2877491B1 (en) 2019-02-27
IL269527A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL269527A (en) Antibodies to the DR5 family, bipolar or multivalent antibodies to the DR5 family and methods of use
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
ZA201406967B (en) Anti sez6 antibodies and methods of use
HUE067282T2 (hu) Anti-CD3 antitestek és alkalmazási módszerek
ZA201308022B (en) Anti-cd40 antibodies and methods of use
ZA201408236B (en) Anti-ly6e antibodies and immunoconjugates and methods of use
IL245862A0 (en) Human anti-tau(ps422) antibodies and methods of use
PH12013500354A1 (en) Anti-ox40 antibodies and methods of using the same
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
IL232055B (en) Anti-1htra antibodies and methods of use
SG11201502757QA (en) Anti-c16orf54 antibodies and methods of use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed